Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


15 Items
Title  Creator  Group name  Publishing year 
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer Viala et al. EquipeCTCS 2021-07-15
Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial Jacot et al. EquipePC 2020-10-09
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer Delrieu et al. EquipeCTCS 2020-07-01
Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial Carayol et al. EquipeCTCS Jul 25, 2019
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers Guiu et al. EquipeELC Jul 2018
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers Viala et al. EquipeCTCS Oct 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabine Etienne-Grimaldi et al. EquipeCG 2017
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Darlix et al. EquipeCTCS 11 15, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients Darlix et al. EquipeCTCS 07 07, 2016
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Lefebvre et al. EquipeELC Dec 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases Jacot et al. EquipeELC 06 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers Ferrari et al. EquipeMY 07 13, 2016
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers Jacot et al. EquipeMY Dec 18, 2015
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Guiu et al. EquipeCTCS Dec 2014
HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort Rouanet et al. EquipeELC Feb 2014
15 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés